Adam F. mentioning a drug means he was either paid to promote that drug or “bash” it. Often times his tweets precede a “hit” article against the company, either from his website or from another website that publishes those types of articles. CYDY made a good move up this week so I don’t doubt those who short stocks are looking at CYDY as a potential target. Given that Adam F. played a part in pumping remdesivir last week, I don’t doubt those who pay him, hedge funds, BP, etc., are concerned about leronlimab’s early success, which is based on limited data. He’ll likely use that limited data to bash the results and the company. He has many, many supporters.
My hope is that the filing of the BLA is announced Monday and that assist in building a stronger floor for the SP, whether that be at $3 or at least above $2. This is not the first nor the last time that Adam F. and traders like him target CYDY.